Survey on the actual situation of treatment in heart failure on admission: A multicenter, use of electronic medical records and claims data, pharmaco-epidemiology, cohort study.(RECOMEND study)

Survey on the actual situation of treatment in heart failure on admission: A multicenter, use of electronic medical records and claims data, pharmaco-epidemiology, cohort study.(RECOMEND study) - Survey on the actual situation of treatment in heart failure on admission: A multicenter, use of electronic medical records and claims data, pharmaco-epidemiology, cohort study.(RECOMEND study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020590

Enrollment

5000

Registered

2016-02-01

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Target Population Patients who were hospitalized for heart failure in acute care hospitals between January 2010 to December 2015. Inclusion Criteria Patients who meet any of the following criteria during any hospitalization will be included. 1) Hospitalization cases due to heart failure (ICD-10: I50) based on any of the following data elements: a) "Diagnosis that triggered hospitalization" b) "Diagnosis with highest medical cost" c) "Main Diagnosis decided by the physician based on medical judgment" 2) Hospitalization cases in which the "Diagnosis with highest medical cost" could be included in any of the following classifications: a) Any diagnosis included in the ICD-10 code list below; b) Patients who received one or more of the listed agents during hospitalization. a) Diagnosis (ICD-10): I21$, I22$, I23$, I24$, I510, I20$, I25$, I420, I421, I422, I423, I424, I425, I426, I427, I428, I429, I43$, I515, I456, I47$, I48, I490, I491, I492, I493, I494, I498, I05$, I06$, I07$, I08$, I34$, I35$, I36$, I37$, I33$, I38, I40$, I41$, I514, I010, I018, I30$, I318, I32$, I310, I311, I50$, I110, I130, I132. $: The numbers from "0" to "9". b) Intravenous Agents: Digoxin, Deslanoside, Amiodarone Hydrochloride, l-Isoprenaline Hydrochloride, Etilefrine Hydrochloride, Noradrenaline, Phenylephrine Hydrochloride,Dopamine Hydrochloride, Dobutamine Hydrochloride, Dipyridamole, Nicorandil, Nitroglycerin, Isosorbide Dinitrate, Olprinone Hydrochloride Hydra, Milrinone, Carperitide, Potassium Canrenoate, Piretanide, Bumetanide, Furosemide, Landiolol Hydrochloride, Diltiazem Hydrochloride, Nicardipine Hydrocloride, Verapamil Hydrochloride. Oral Agents: Eplerenone, Spironolacton, Azosemide, Torasemide, Piretanide, Bumetanide, Furosemide, Indapamide, Trichlormethiazide, Hydrochlorothiazide, Tolvaptan.

Exclusion criteria

Exclusion criteria: Age < 20 years old (on admission)

Design outcomes

Primary

Measure	Time frame
1.Hospitalization length 2.In-hospital death	—

Countries

Japan

Contacts

Public ContactHiromichi Chikashima

Otsuka Pharmaceutical Co., Ltd. Medical Affairs

Recomend_study@otsuka.jp03-6717-1400

Outcome results